Evidence map›Paper›PMID 42399411›Full record

ArticleScientific reports2026

Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.

David Lebeaux, Estelle Lu, Béatrice Parfait, Aurélie Vilfaillot, Cléo Bourgeois, Marie Lachatre, Nathalie Demory, Michaela Semeraro, Bénédicte Sawicki, Damien Sene and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

David LebeauxDépartement des Maladies Infectieuses Saint-Louis-Lariboisière, Institut Pasteur, Université Paris Cité, CNRS UMR 6047, Genetics of Biofilms Laboratory, 2 rue Ambroise Paré, 75010, Paris, France. david.lebeaux@aphp.fr.ORCID https://orcid.org/0000-0002-7164-831X
Estelle Lu *INSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, 75015, Paris, France.
Béatrice Parfait *CRB Cochin, Hôpital Cochin et Fédération des CRB/PRB AP-HP, Centre-Université Paris Cité, 123 bd de Port Royal, 75014, Paris, France.
Aurélie Vilfaillot *INSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, 75015, Paris, France.
Cléo BourgeoisINSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, 75015, Paris, France.
Marie LachatreINSERM, Centre d'Investigation Clinique (CIC) 1417 Cochin Pasteur, French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, APHP, Hôpital Cochin, Université Paris Cité, Paris, France.
Nathalie DemoryService de Santé au Travail, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
Michaela SemeraroUnité de Recherche clinique/Centre d'Investigation Clinique Necker P1419 Necker Cochin, GHU Paris Centre Université Paris Cité, AP-HP, 75015, Paris, France.
Bénédicte SawickiService de Santé au Travail, Hôpital Bichat, APHP, Nord-Université Paris Cité, 46 rue Henri Huchard, 75018, Paris, France.
Damien SeneService de Médecine Interne, Hôpital Lariboisière AP-HP, Nord-Université Paris Cité, 2 rue Ambroise Paré, 75010, Paris, France.
Martine LouëtService de Santé au Travail, la Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Bruno PinnaUNICO-GRECO Cardio-Oncology Program, Sorbonne Université, AP-HP, 75013, Paris, France.
Benoit VédiéCRB, Hôpital Européen Georges Pompidou, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015, Paris, France.
Daniela GerominCRB, Hôpital Européen Georges Pompidou, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015, Paris, France.
Marie-Alexandra AlyanakianCRB, Hôpital Necker Enfants Malades, AP-HP, Centre-Université Paris Cité, 149 rue de Sevres, 75015, Paris, France.
Sarah TubianaCRB Biothèque, Hôpital Bichat, AP-HP, Nord-Université Paris Cité, 46 rue Henri Huchard, 75018, Paris, France.
Philippe ManivetBioBank Lariboisière, AP-HP, Nord-Université Paris Cité, 2 rue Ambroise Paré, 75010, Paris, France.
Jean-Marc LacortePlateforme de Ressources Biologiques, Hôpital Pitié Salpêtrière, AP-HP, Sorbonne Université, 47/83 Bd de l'Hôpital, 75013, Paris, France.
Gérard FriedlanderFondation Université Paris Cité, Paris, France.
Hélène PéréVirology Laboratory, Hôpital Européen Georges-Pompidou, APHP, Centre-Université Paris Cité, Paris, France.
Xavier DuvalUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm 1137, IAME, 75018, Paris, France.
Pauline JouanyINSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, 75015, Paris, France.
Juliette Djadi-PratINSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, 75015, Paris, France.
Solen Kernéis *Université Paris Cité, INSERM, IAME, 75018, Paris, France.
Marie Courbebaisse *Université Paris Cité, Paris, France.
COVID-HOP Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Healthcare workers (HCW) have been at the frontline during the COVID-19 pandemic, with an increased risk of infection, particularly due to the emergence of the omicron variant. This study aims to assess risk factors for omicron acquisition among vaccinated HCW, comparing hybrid immunity (previous infection and vaccination) to vaccine-induced immunity alone. We took advantage of the COVID-HOP prospective cohort, which includes vaccinated HCW followed over several months, collecting detailed data on demographic characteristics, comorbidities, and professional and personal exposures to COVID-19. We analyzed factors associated with omicron acquisition after January 2022, with a focus on immunization scheme (hybrid or vaccine-induced immunity). Out of 698 HCW analyzed, 298 acquired the omicron variant. In the multivariable analysis (taking into account comorbidities, professional/personal exposure and lifestyle), the two independent factors associated with an increased risk of infection were: younger age (P = 0.005) and immunization scheme (OR associated with vaccine-induced immunity alone: 2.43 [95% Confidence Interval: 1.64-3.60]) with hybrid immunity as reference). HCW with hybrid immunity have a reduced risk of acquiring omicron compared to those with vaccine-induced immunity alone. These findings emphasize the importance of a combined vaccination strategy to better protect HCW against emerging variants, and to vaccine HCW who experienced previous COVID-19 episodes.

Indexed as

COVID-19Health PersonnelSARS-CoV-2AdultCOVID-19 VaccinesFemaleFranceHumansMaleMiddle AgedProspective StudiesRisk FactorsVaccinationCOVID-19 VaccinesCOVID-19Healthcare workersHybrid immunitySARS-CoV-2Vaccine

Identifiers

PMID42399411
PMCPMC13396384

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.